Agonistic TAM-163 antibody targeting tyrosine kinase receptor-B

References

• Lebrun B, Bariohay B, Moyse E, Jean A. Brain-derived neurotrophic factor (BDNF) and food intake regulation: a minireview. Auton Neurosci 2006; 126-127:30 - 8; http://dx.doi.org/10.1016/j.autneu.2006.02.027; PMID: 16632412
   PubMed Web of Science ®Google Scholar
• Shibayama E, Koizumi H. Cellular localization of the Trk neurotrophin receptor family in human non-neuronal tissues. Am J Pathol 1996; 148:1807 - 18; PMID: 8669468
   PubMed Web of Science ®Google Scholar
• Lin JC, Tsao D, Barras P, Bastarrachea RA, Boyd B, Chou J, et al. Appetite enhancement and weight gain by peripheral administration of TrkB agonists in non-human primates. PLoS One 2008; 3:e1900; http://dx.doi.org/10.1371/journal.pone.0001900; PMID: 18382675
   PubMedGoogle Scholar
• Tsao D, Thomsen HK, Chou J, Stratton J, Hagen M, Loo C, et al. TrkB agonists ameliorate obesity and associated metabolic conditions in mice. Endocrinology 2008; 149:1038 - 48; http://dx.doi.org/10.1210/en.2007-1166; PMID: 18063676
   PubMed Web of Science ®Google Scholar
• Hünig T. The storm has cleared: lessons from the CD28 superagonist TGN1412 trial. Nat Rev Immunol 2012; 12:317 - 8; http://dx.doi.org/10.1038/nri3192-c2; PMID: 22487653
   PubMed Web of Science ®Google Scholar
• Ling J, Zhou H, Jiao Q, Davis HM. Interspecies scaling of therapeutic monoclonal antibodies: initial look. J Clin Pharmacol 2009; 49:1382 - 402; http://dx.doi.org/10.1177/0091270009337134; PMID: 19837907
   PubMed Web of Science ®Google Scholar
• Mahmood I. Pharmacokinetic allometric scaling of antibodies: application to the first-in-human dose estimation. J Pharm Sci 2009; 98:3850 - 61; http://dx.doi.org/10.1002/jps.21682; PMID: 19177515
   PubMed Web of Science ®Google Scholar
• Mordenti J, Chen SA, Moore JA, Ferraiolo BL, Green JD. Interspecies scaling of clearance and volume of distribution data for five therapeutic proteins. Pharm Res 1991; 8:1351 - 9; http://dx.doi.org/10.1023/A:1015836720294; PMID: 1798669
   PubMed Web of Science ®Google Scholar
• Oitate M, Masubuchi N, Ito T, Yabe Y, Karibe T, Aoki T, et al. Prediction of human pharmacokinetics of therapeutic monoclonal antibodies from simple allometry of monkey data. Drug Metab Pharmacokinet 2011; 26:423 - 30; http://dx.doi.org/10.2133/dmpk.DMPK-11-RG-011; PMID: 21606605
   PubMed Web of Science ®Google Scholar
• Vugmeyster Y, Szklut P, Tchistiakova L, Abraham W, Kasaian M, Xu X. Preclinical pharmacokinetics, interspecies scaling, and tissue distribution of humanized monoclonal anti-IL-13 antibodies with different IL-13 neutralization mechanisms. Int Immunopharmacol 2008; 8:477 - 83; http://dx.doi.org/10.1016/j.intimp.2007.12.004; PMID: 18279802
   PubMed Web of Science ®Google Scholar
• Betts AM, Clark TH, Yang J, Treadway JL, Li M, Giovanelli MA, et al. The application of target information and preclinical pharmacokinetic/pharmacodynamic modeling in predicting clinical doses of a Dickkopf-1 antibody for osteoporosis. J Pharmacol Exp Ther 2010; 333:2 - 13; http://dx.doi.org/10.1124/jpet.109.164129; PMID: 20089807
   PubMed Web of Science ®Google Scholar
• Luu KT, Bergqvist S, Chen E, Hu-Lowe D, Kraynov E. A model-based approach to predicting the human pharmacokinetics of a monoclonal antibody exhibiting target-mediated drug disposition. J Pharmacol Exp Ther 2012; 341:702 - 8; http://dx.doi.org/10.1124/jpet.112.191999; PMID: 22414855
   PubMed Web of Science ®Google Scholar
• Aston PJ, Derks G, Raji A, Agoram BM, van der Graaf PH. Mathematical analysis of the pharmacokinetic-pharmacodynamic (PKPD) behaviour of monoclonal antibodies: predicting in vivo potency. J Theor Biol 2011; 281:113 - 21; http://dx.doi.org/10.1016/j.jtbi.2011.04.030; PMID: 21557949
   PubMed Web of Science ®Google Scholar
• Dong JQ, Salinger DH, Endres CJ, Gibbs JP, Hsu CP, Stouch BJ, et al. Quantitative prediction of human pharmacokinetics for monoclonal antibodies: retrospective analysis of monkey as a single species for first-in-human prediction. Clin Pharmacokinet 2011; 50:131 - 42; http://dx.doi.org/10.2165/11537430-000000000-00000; PMID: 21241072
   PubMed Web of Science ®Google Scholar
• Gibiansky L, Gibiansky E. Target-mediated drug disposition model for drugs that bind to more than one target. J Pharmacokinet Pharmacodyn 2010; 37:323 - 46; http://dx.doi.org/10.1007/s10928-010-9163-3; PMID: 20669044
   PubMed Web of Science ®Google Scholar
• Mager DE. Target-mediated drug disposition and dynamics. Biochem Pharmacol 2006; 72:1 - 10; http://dx.doi.org/10.1016/j.bcp.2005.12.041; PMID: 16469301
   PubMed Web of Science ®Google Scholar
• Yu J, Karcher H, Feire AL, Lowe PJ. From target selection to the minimum acceptable biological effect level for human study: use of mechanism-based PK/PD modeling to design safe and efficacious biologics. AAPS J 2011; 13:169 - 78; http://dx.doi.org/10.1208/s12248-011-9256-y; PMID: 21336535
   PubMed Web of Science ®Google Scholar
• Dirks NL, Meibohm B. Population pharmacokinetics of therapeutic monoclonal antibodies. Clin Pharmacokinet 2010; 49:633 - 59; http://dx.doi.org/10.2165/11535960-000000000-00000; PMID: 20818831
   PubMed Web of Science ®Google Scholar
• Muller PY, Milton M, Lloyd P, Sims J, Brennan FR. The minimum anticipated biological effect level (MABEL) for selection of first human dose in clinical trials with monoclonal antibodies. Curr Opin Biotechnol 2009; 20:722 - 9; http://dx.doi.org/10.1016/j.copbio.2009.10.013; PMID: 19896825
   PubMed Web of Science ®Google Scholar
• Agoram BM. Use of pharmacokinetic/ pharmacodynamic modelling for starting dose selection in first-in-human trials of high-risk biologics. Br J Clin Pharmacol 2009; 67:153 - 60; http://dx.doi.org/10.1111/j.1365-2125.2008.03297.x; PMID: 19076987
   PubMed Web of Science ®Google Scholar
• Lowe PJ, Tannenbaum S, Gautier A, Jimenez P. Relationship between omalizumab pharmacokinetics, IgE pharmacodynamics and symptoms in patients with severe persistent allergic (IgE-mediated) asthma. Br J Clin Pharmacol 2009; 68:61 - 76; http://dx.doi.org/10.1111/j.1365-2125.2009.03401.x; PMID: 19660004
   PubMed Web of Science ®Google Scholar
• Chen ZY, Ieraci A, Tanowitz M, Lee FS. A novel endocytic recycling signal distinguishes biological responses of Trk neurotrophin receptors. Mol Biol Cell 2005; 16:5761 - 72; http://dx.doi.org/10.1091/mbc.E05-07-0651; PMID: 16207814
   PubMed Web of Science ®Google Scholar
• Grimwood S, Hartig PR. Target site occupancy: emerging generalizations from clinical and preclinical studies. Pharmacol Ther 2009; 122:281 - 301; http://dx.doi.org/10.1016/j.pharmthera.2009.03.002; PMID: 19306894
   PubMed Web of Science ®Google Scholar
• Deng R, Iyer S, Theil FP, Mortensen DL, Fielder PJ, Prabhu S. Projecting human pharmacokinetics of therapeutic antibodies from nonclinical data: what have we learned?. MAbs 2011; 3:61 - 6; http://dx.doi.org/10.4161/mabs.3.1.13799; PMID: 20962582
   PubMed Web of Science ®Google Scholar
• Kagan L, Abraham AK, Harrold JM, Mager DE. Interspecies scaling of receptor-mediated pharmacokinetics and pharmacodynamics of type I interferons. Pharm Res 2010; 27:920 - 32; http://dx.doi.org/10.1007/s11095-010-0098-6; PMID: 20232116
   PubMed Web of Science ®Google Scholar
• Zheng J, Shen WH, Lu TJ, Zhou Y, Chen Q, Wang Z, et al. Clathrin-dependent endocytosis is required for TrkB-dependent Akt-mediated neuronal protection and dendritic growth. J Biol Chem 2008; 283:13280 - 8; http://dx.doi.org/10.1074/jbc.M709930200; PMID: 18353779
   PubMed Web of Science ®Google Scholar
• Chan PL, Jacqmin P, Lavielle M, McFadyen L, Weatherley B. The use of the SAEM algorithm in MONOLIX software for estimation of population pharmacokinetic-pharmacodynamic-viral dynamics parameters of maraviroc in asymptomatic HIV subjects. J Pharmacokinet Pharmacodyn 2011; 38:41 - 61; http://dx.doi.org/10.1007/s10928-010-9175-z; PMID: 21088872
   PubMed Web of Science ®Google Scholar
• Mager DE, Krzyzanski W. Quasi-equilibrium pharmacokinetic model for drugs exhibiting target-mediated drug disposition. Pharm Res 2005; 22:1589 - 96; http://dx.doi.org/10.1007/s11095-005-6650-0; PMID: 16180117
   PubMed Web of Science ®Google Scholar
• Gibiansky L, Gibiansky E, Kakkar T, Ma P. Approximations of the target-mediated drug disposition model and identifiability of model parameters. J Pharmacokinet Pharmacodyn 2008; 35:573 - 91; http://dx.doi.org/10.1007/s10928-008-9102-8; PMID: 19005743
   PubMed Web of Science ®Google Scholar